Kevin Tang bought $845K of Fulcrum Therapeutics (FULC)
Executed Jul 14, disclosed Jul 15, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Jul 15), the stock returned +6.7% (delay-adjusted); from the execution session (Jul 14), +4.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Kevin Tang (Director) filed 9 Form 4 reports in the trailing twelve months (9 purchases, 0 sales), most often in Aurinia Pharmaceuticals Inc. (AUPH). Across 8 priced purchase filings, the average 21-session return was +4.8% from execution and +6.8% from disclosure (delay-adjusted; derived). The largest single filing was $12.7M of AUPH (898,400 sh across 5 lots, as filed), executed Feb 27.
Healthcare · Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with gene…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→167,616 sh across 2 lots
Exec Jul 16
Filed Jul 20 · 9:10 PM ET